Danaher Corporation vs Merck & Company, Inc. — Stock Comparison

DHR
Danaher Corporation
$175.15
▼ 2.12%
vs
MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
Q·Score Winner
Danaher Corporation
DHR7.7/10vs 6.7/10

Q·Score Breakdown

7.7
Bullish
Overall
6.7
Neutral
6.7
Quality
6.2
9.1
Health
7
6.2
Growth
6.2
8.6
Valuation
7.2
8.6
Sentiment
7.1
DHR

Clean balance sheet with low leverage (0.4× debt-to-equity).

MRK

Forward P/E of 11.5× is low relative to sector peers.

Analyst Consensus

BUY
Target $250.14 (+42.8%)
22 analysts
BUY
Target $129.74 (+15.7%)
27 analysts

Fundamentals

DHR
MRK
33.9×
Trailing P/E
31.5×
19.3×
Forward P/E
11.5×
14.9%
Profit Margin
13.6%
59.0%
Gross Margin
76.6%
7.1%
ROE
3.7%
Revenue Growth
4.9%
9.8%
Earnings Growth
0.99
Beta
0.28
Price / Book
$124.0B
Market Cap
$277.0B
$175 – $243
52-Week Range
$73 – $125

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →